My view for AstraZeneca on LSEMy View on AstraZeneca (LSE)
After analysing AstraZeneca on the monthly time frame, I observed the formation of a W-pattern, with the right leg currently developing. Although there has been a pullback on the right-hand side, I consider this a potential buying opportunity, particularly when supporte
Key facts today
AstraZeneca's stock closed at 1,559.50 SEK, marking an increase of 7.50 SEK or 0.48% in the latest trading session.
0.95 USD
6.25 B USD
48.03 B USD
About AstraZeneca PLC
Sector
Industry
CEO
Pascal Soriot
Website
Headquarters
Cambridge
Founded
1913
ISIN
ARDEUT112489
FIGI
BBG000DDGBJ4
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company’s history roots back to the year 1913 when Astra business was formed. AstraZeneca was founded in 1999 through the merger of Astra AB and Zeneca Group PLC. The company is headquartered in Cambridge, the United Kingdom.
Related stocks
AZN Stock Going UP, Confirmed Monday 8/11/25Hello, 
Ayrfolio trade ideas are based on weekly charts and momentum, so remember to be patient! No day trades here unless the stock soars up intraday. Today we’re covering: 
COMPANY: Astrazeneca PLC
STOCK SYMBOL: AZN
POSITION: Long
TP1 Risk-Reward Ratio: 1.67
TP2 Risk-Reward Ratio: 2.0
Stop Loss:
Supply and Demand Trading Made Simple With Astrazeneca StockIn the ever-evolving world of stock trading, where news headlines can shift markets in a heartbeat, savvy investors often turn to the age-old principles of supply and demand to find clarity. Enter AstraZeneca stock (NASDAQ: AZN) — a biopharmaceutical titan that has played a pivotal role in global he
Astrazeneca potentially to $88AstraZeneca’s share price has been hovering around a long-term trend line established since 2017. Historically, each time the price has tested this trend line, it has rebounded sharply, suggesting strong investor confidence.
From 2017 to 2023, the company’s financial performance has been notably ro
BULLISH ON AZNAstraZeneca's Q3 2024 earnings exceeded expectations, with a revenue increase of 18%, signaling healthy demand for its products, especially in oncology and rare diseases.
 Technicals - Key Indicators: 
RSI (Relative Strength Index): Currently at 41.08, indicating strong bullish momentum but not ye
Astrazeneca (Wait for correction to complete)Hello,
To demonstrate how we can leverage TradingView for informed investment decisions, let’s analyze AstraZeneca as our example today. I will follow a structured approach and provide an investment recommendation based on both fundamental and technical insights.
 Understanding the Business 
Befor
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where AZND is featured.













